Theratechnologies gets exclusive rights to sell TaiMed's HIV therapy in the US and Canada; deal ends
Under a 12-year deal, TaiMed Biologics Inc. licensed Theratechnologies Inc. exclusive rights to market and distribute the HIV candidate ibalizumab in the US and in Canada.
- Large Molecule
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.